Loading...
By Amy Orciari Herman
Edited by André Sofair, MD, MPH, and William E. Chavey, MD, MS
Adding the injectable type 2 diabetes drug exenatide (Byetta) to usual care does not improve cardiovascular outcomes, according to an industry-funded, international trial published in the New England Journal of Medicine and presented at the European Association for the Study of Diabetes's annual meeting.
Nearly 15,000 adults were randomized to add weekly injections of exenatide or placebo to their usual type 2 diabetes regimens. About three-fourths of participants had a prior CV event.
During a median follow-up of 3 years, incidence of the primary composite outcome — CV death, nonfatal MI, or nonfatal stroke — did not differ significantly between the exenatide and placebo groups (11.4% and 12.2%, respectively). Results were similar regardless of the patient's history of CV disease.
The authors conclude that exenatide "was noninferior to placebo with respect to cardiovascular safety but was not superior to placebo with respect to efficacy."
Comment
LINK(S):
NEJM article (Free)
Background: Recent NEJM Journal Watch General Medicine coverage of exenatide (and other diabetes drugs) & mortality (Your NEJM Journal Watch subscription required)